{
    "elements": [
        {
            "type": "image",
            "sequence_num": 1,
            "data": {
                "url": "08056 Management of human immunodeficiency virus (HIV) in pregnancy 5.1.001.png"
            }
        },
        {
            "type": "table",
            "sequence_num": 2,
            "data": {
                "num_rows": 15,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "Document Title:"
                    },
                    {
                        "text": "MANAGEMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN MATERNITY"
                    },
                    {
                        "text": "Document Reference/Register no:"
                    },
                    {
                        "text": "08056"
                    },
                    {
                        "text": "Version Number:"
                    },
                    {
                        "text": "5.1"
                    },
                    {
                        "text": "Document type: (Policy/ Guideline/ SOP)"
                    },
                    {
                        "text": "Guideline"
                    },
                    {
                        "text": "To be followed by: (Target Staff)"
                    },
                    {
                        "text": "Obstetricians and Midwifery staff"
                    },
                    {
                        "text": "Ratification Issue Date: (Date document is uploaded onto the intranet)"
                    },
                    {
                        "text": "03 August 2020"
                    },
                    {
                        "text": "Review Date:"
                    },
                    {
                        "text": "02 August 2023"
                    },
                    {
                        "text": "Developed in response to:"
                    },
                    {
                        "text": "British HIV Association guideline RCOG guideline"
                    },
                    {
                        "text": "Contributes to HSC Act 2008 (Regulated Activities) Regulations 2014(Part 3); and CQC Regulations 2009 (Part 4) CQC Fundamental Standards of Quality and Safety:"
                    },
                    {
                        "text": "9,11"
                    },
                    {
                        "text": "Issuing Division/Directorate:"
                    },
                    {
                        "text": "Obstetrics and Gynaecology"
                    },
                    {
                        "text": "Author/Contact: (Asset Administrator)"
                    },
                    {
                        "text": "Emma Neate, Antenatal and Newborn Screening Co- ordinator Dr Alina Maria Unipan SpR OBGYN MBBS MRCOG"
                    },
                    {
                        "text": "Hospital Sites: (tick appropriate box/es to indicate status of policy review i.e. joint/ independent)"
                    },
                    {
                        "text": "\u2610 MSE NHS Foundation Trust \u2610 Basildon Hospital \u2612 Broomfield Hospital \u2610 Southend Hospital \u2610 Other (please state)"
                    },
                    {
                        "text": "Consultation:"
                    },
                    {
                        "text": "(Refer to page 2)"
                    },
                    {
                        "text": "Approval Group / Committee(s):"
                    },
                    {
                        "text": "n/a"
                    },
                    {
                        "text": "Date:"
                    },
                    {
                        "text": "n/a"
                    },
                    {
                        "text": "Professionally Approved by: (Asset Owner)"
                    },
                    {
                        "text": "Miss A Rao, Lead Consultant for Obstetrics and Gynaecology"
                    },
                    {
                        "text": "Date:"
                    },
                    {
                        "text": "08 April 2020"
                    },
                    {
                        "text": "Ratification Group(s):"
                    },
                    {
                        "text": "Joint Document Management Group"
                    },
                    {
                        "text": "Date:"
                    },
                    {
                        "text": "14 July 2020"
                    },
                    {
                        "text": "Executive and Clinical Directors (Communication of minutes from Document Ratification Group"
                    },
                    {
                        "text": "Date: August 2020"
                    },
                    {
                        "text": "Distribution Method:"
                    },
                    {
                        "text": "Trust Intranet/ Internet"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "image",
            "sequence_num": 3,
            "data": {
                "url": "08056 Management of human immunodeficiency virus (HIV) in pregnancy 5.1.002.png"
            }
        },
        {
            "type": "table",
            "sequence_num": 4,
            "data": {
                "num_rows": 12,
                "num_cols": 2,
                "table_items": [
                    {
                        "text": "Consulted With:"
                    },
                    {
                        "text": "Post/ Approval Committee/ Group:"
                    },
                    {
                        "text": "Date:"
                    },
                    {
                        "text": "Anita Rao"
                    },
                    {
                        "text": "Clinical Director for Women and Children"
                    },
                    {
                        "text": "13 February 2020"
                    },
                    {
                        "text": "Vidya Thakur"
                    },
                    {
                        "text": "Consultant for Obstetrics and Gynaecology"
                    },
                    {
                        "text": "Roslyn Bullen-Bell"
                    },
                    {
                        "text": "Head of Midwifery"
                    },
                    {
                        "text": "Amanda Dixon"
                    },
                    {
                        "text": "Lead Midwife for Labour Ward and Acute In-patient service"
                    },
                    {
                        "text": "Chris Berner"
                    },
                    {
                        "text": "Lead Midwife for Clinical Governance"
                    },
                    {
                        "text": "Angela Woolfenden"
                    },
                    {
                        "text": "Lead Midwife for Community Services"
                    },
                    {
                        "text": "Sarah Iskander"
                    },
                    {
                        "text": "Antenatal Clinical Midwife"
                    },
                    {
                        "text": "Dr Price"
                    },
                    {
                        "text": "Consultant Physician in HIV"
                    },
                    {
                        "text": "Dr Teare"
                    },
                    {
                        "text": "Consultant Microbiologist"
                    },
                    {
                        "text": "Dr Morrossey"
                    },
                    {
                        "text": "Consultant Microbiologist"
                    },
                    {
                        "text": "Claire Fitzgerald"
                    },
                    {
                        "text": "Pharmacist"
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 5,
            "data": {
                "num_rows": 1,
                "num_cols": 2,
                "table_items": [
                    {
                        "text": "Related Trust Policies (to be read in conjunction with)"
                    },
                    {
                        "text": "(Refer to the main body of the text) 07056 Management of Neonates Born to HIV positive mother 04071 Standard Infection Prevention 04072 Hand Hygiene 06036 Guideline for Maternity Record Keeping including Documentation in Handheld Records 06031 Receiving and Acting on Test Results in Maternity by both Hospital and Community 04272 Maternity Care"
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 6,
            "data": {
                "num_rows": 10,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "Document Review History:"
                    },
                    {
                        "text": "Version No:"
                    },
                    {
                        "text": "Authored/Reviewer:"
                    },
                    {
                        "text": "Summary of amendments:"
                    },
                    {
                        "text": "Issue Date:"
                    },
                    {
                        "text": "1.0"
                    },
                    {
                        "text": "Kathleen Bird"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "July 2009"
                    },
                    {
                        "text": "1.1"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "Equality and diversity, audit and monitoring update"
                    },
                    {
                        "text": "January 2010"
                    },
                    {
                        "text": "2.0"
                    },
                    {
                        "text": "Nicky Leslie"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "February 2012"
                    },
                    {
                        "text": "2.1"
                    },
                    {
                        "text": "Nicky Leslie"
                    },
                    {
                        "text": "Clarification to point 25 and Appendix A, D, G"
                    },
                    {
                        "text": "June 2013"
                    },
                    {
                        "text": "3.0"
                    },
                    {
                        "text": "Nicky Leslie"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "10 November 2015"
                    },
                    {
                        "text": "4.0"
                    },
                    {
                        "text": "Emma Neate"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "October 2018"
                    },
                    {
                        "text": "5.0"
                    },
                    {
                        "text": "Emma Neate and Dr Alina Maria Unipan"
                    },
                    {
                        "text": "Full Review: Review of current guidelines in line with British HIV Association; clarification to points 2.0, 21.0"
                    },
                    {
                        "text": "03 August 2020"
                    },
                    {
                        "text": "5.1"
                    },
                    {
                        "text": "Rachel Smith"
                    },
                    {
                        "text": "Clarification to point 3.1 and 25.5 addition of hyperlink for BHIVA guideline. Update to Appendix F"
                    },
                    {
                        "text": "01 September 2021"
                    }
                ]
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 7,
            "data": {
                "is_heading": 1,
                "text": "Contents"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 8,
            "data": {
                "is_heading": 1,
                "prefix": 1.0,
                "text": "Purpose\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026..\u2026\u2026\u2026\u2026..5"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 9,
            "data": {
                "is_heading": 1,
                "prefix": 3.0,
                "text": "Equality Impact Assessment\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026.................\u2026.....\u2026.... 5  Rationale for Recommendations...........................................................................5"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 10,
            "data": {
                "is_heading": 1,
                "prefix": 7.0,
                "text": "Roles and Responsibilities\u2026\u2026\u2026.............\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026...\u2026\u2026\u2026\u2026\u2026\u2026.........5  Routine Screening in Antenatal Clinic \u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026..\u2026\u2026.7  Antepartum Management of HIV+ve Mothers \u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026....10  Mother\u2013To-Child Transmission of HIV ............................................................. 12"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 11,
            "data": {
                "is_heading": 1,
                "prefix": 25.0,
                "text": "Antiretroviral Therapy \u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026......13 Zidovudine Monotherapy \u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026....13  Anti-Retroviral Therapy (ART) \u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026.\u202613  Patients who conceive on Therapy \u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026...\u202614  Patient presenting after  weeks gestation\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u202614  Viral Load\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026......14  Genotypic Resistance Testing\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026.\u202614  Pneumoncystis Carinii Pneumonia (PCP) Prophylaxis\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026.\u202615  Complications during Pregnancy\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026...15  External cephalic version in patients with HIV\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u202615  HIV-2 infected Patients\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u202616  Neonatologist Referral\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u202616  HIV and Hepatitis B and C Co -infected patients\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026..\u2026..16  Intrapartum Management\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026..\u202617  IV Zidovudine Regimen\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026.\u202618  Management of Unplanned Delivery\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026.\u202619  Perinatal Mental Health in Women with HIV\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026..\u2026\u2026\u2026.\u2026\u202619  Postpartum Management and Breastfeeding\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026.\u202619"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 12,
            "data": {
                "is_heading": 1,
                "prefix": 32.0,
                "text": "Neonatal Management\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026.\u2026.20  Staff and Training\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026.\u2026.20  Infection Prevention\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026.\u2026.20  Audit and Monitoring\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u202620  Guideline Management\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026.\u202621  Approval and Implementation\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026.\u2026\u2026\u2026\u2026\u2026\u2026\u2026..\u2026.21  References \u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026...\u2026..22 Appendix A - Retroviral Infection Care Plan"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 13,
            "data": {
                "is_heading": 0,
                "text": "Appendix B - Neonatal Alert Form"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 14,
            "data": {
                "is_heading": 0,
                "text": "Appendix C - Receiving HIV Blood Results"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 15,
            "data": {
                "is_heading": 0,
                "text": "Appendix D - Contact Names and Telephone Numbers"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 16,
            "data": {
                "is_heading": 0,
                "text": "Appendix E - Antenatal and Newborn Screening- HIV Screening"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 17,
            "data": {
                "is_heading": 0,
                "text": "Appendix F - Out of Hours Infectious Diseases Screening in Maternity Services Appendix G - Equality Impact Assessment"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 18,
            "data": {
                "is_heading": 0,
                "text": "Management of Human Immunodeficiency Virus (HIV) in Maternity / 08056 / 5.1"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 19,
            "data": {
                "is_heading": 1,
                "prefix": 35.0,
                "text": "Page  of"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 20,
            "data": {
                "is_heading": 1,
                "prefix": 1.0,
                "text": "Purpose"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 21,
            "data": {
                "is_heading": 0,
                "prefix": 1.1,
                "text": "To provide guidance on the management of maternal human immunodeficiency virus (HIV) in pregnancy; in order to reduce the risk of vertical transmission of HIV to the neonate."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 22,
            "data": {
                "is_heading": 1,
                "prefix": 2.0,
                "text": "Equality Impact Assessment"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 23,
            "data": {
                "is_heading": 0,
                "prefix": 2.1,
                "text": "Mid and South Essex NHS Foundation Trust is committed to the provision of a service that is fair, accessible and meets the needs of all individuals (refer to Appendix 1)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 24,
            "data": {
                "is_heading": 0,
                "prefix": 2.2,
                "text": "All women accessing care at Mid and South Essex Maternity Units have the same access to screening, subsequent diagnostic testing and outcomes in line with the Equality Act 2010."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 25,
            "data": {
                "is_heading": 0,
                "prefix": 2.3,
                "text": "The Trust have procedures in place to identify and support those persons who are considered vulnerable/ hard-to-reach including:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 26,
            "data": {
                "is_heading": 0,
                "text": "Those who are not registered with a GP;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 27,
            "data": {
                "is_heading": 0,
                "text": "Homeless people / rough sleepers;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 28,
            "data": {
                "is_heading": 0,
                "text": "Asylum seekers;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 29,
            "data": {
                "is_heading": 0,
                "text": "Gypsy and traveller groups;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 30,
            "data": {
                "is_heading": 0,
                "text": "Sex workers;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 31,
            "data": {
                "is_heading": 0,
                "text": "Those in prison;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 32,
            "data": {
                "is_heading": 0,
                "text": "Those with mental health problems;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 33,
            "data": {
                "is_heading": 0,
                "text": "Those with drug or alcohol harm issues;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 34,
            "data": {
                "is_heading": 0,
                "text": "Those with learning disabilities;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 35,
            "data": {
                "is_heading": 0,
                "text": "Physical disabilities or communications difficulties."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 36,
            "data": {
                "is_heading": 1,
                "prefix": 3.0,
                "text": "Rationale for Recommendations"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 37,
            "data": {
                "is_heading": 0,
                "prefix": 3.1,
                "text": "This guideline is written with reference to the British HIV Association (BHIVA) 2019 Guidelines for the Management of HIV infection in Pregnant Women available at https://www.bhiva.org/pregnancy-guidelines  and the Prevention of Mother-to-child Transmission, the Infectious Diseases in Pregnancy Screening Standards 2016-2017."
            }
        },
        {
            "type": "table",
            "sequence_num": 38,
            "data": {
                "num_rows": 3,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "Screening Standards"
                    },
                    {
                        "text": "Definition"
                    },
                    {
                        "text": "Evidence in Guideline of Standard"
                    },
                    {
                        "text": "IDPS-S01"
                    },
                    {
                        "text": "The proportion of pregnant women eligible for HIV screening for whom a confirmed screening result"
                    },
                    {
                        "text": "See section 4.3"
                    },
                    {
                        "text": "IDPS-S04"
                    },
                    {
                        "text": "Number of results for each infection (confirmed positive or negative) reported to maternity services \u2264 8 working days of sample receipt in the laboratory."
                    },
                    {
                        "text": "See section 4.5"
                    }
                ]
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 39,
            "data": {
                "is_heading": 0,
                "text": "IDPS-S05 Number of women with confirmed positive See section 4.5"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 40,
            "data": {
                "is_heading": 0,
                "text": "results who attend a screening assessment"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 41,
            "data": {
                "is_heading": 0,
                "prefix": 10.0,
                "text": "appointment \u2264  working days."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 42,
            "data": {
                "is_heading": 0,
                "prefix": 3.2,
                "text": "A key goal of managing HIV in pregnancy and postpartum is to optimise a woman's own health and reduce vertical transmission. Furthermore, one of the major successes in the management of individuals living with HIV has been the prevention of vertical transmission of HIV. With the widespread implementation of routine antenatal screening for HIV, vertical transmission is now a rare occurrence in the UK \u2013 fewer than 5 per year."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 43,
            "data": {
                "is_heading": 0,
                "prefix": 3.3,
                "text": "Antenatal screening and early detection of maternal infection is vital to reduce vertical transmission therefore the recommendation for antenatal HIV testing was introduced in England in 2000 and throughout the UK by 2002. National uptake rates improved year on year, and uptake has exceeded 97% since 2011."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 44,
            "data": {
                "is_heading": 0,
                "prefix": 3.4,
                "text": "The risk of mother to baby (vertical) transmission of HIV can be reduced from 25% to less than 1% with the following interventions when appropriate."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 45,
            "data": {
                "is_heading": 0,
                "text": "Antiretroviral therapy antepartum and intrapartum;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 46,
            "data": {
                "is_heading": 0,
                "text": "Antiretroviral therapy to the neonate;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 47,
            "data": {
                "is_heading": 0,
                "text": "Avoidance of breastfeeding;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 48,
            "data": {
                "is_heading": 0,
                "text": "Discussion on the mode of delivery and possible pre-labour caesarean section."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 49,
            "data": {
                "is_heading": 0,
                "prefix": 3.5,
                "text": "Since the majority of vertical transmission occurs during the intrapartum period, it is important that medical, midwifery and nursing staff are familiar with the management of HIV in pregnancy."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 50,
            "data": {
                "is_heading": 0,
                "prefix": 3.6,
                "text": "Management of a patient with HIV should be provided by a multidisciplinary team formed by Obstetrician, Paediatrician, Consultant for HIV and Specialist HIV Team."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 51,
            "data": {
                "is_heading": 1,
                "prefix": 3.7,
                "text": "What is HIV?"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 52,
            "data": {
                "is_heading": 0,
                "text": "3.7.1 Human immunodeficiency virus (HIV) is a retro-virus, which, if left untreated, leads to immunosuppression and eventually to acquired immune deficiency syndrome (AIDS). HIV is present in all body fluids such as blood, semen, vaginal secretions and breast milk. It can be passed on through unprotected sexual intercourse, direct contact with the blood of an infected person, sharing infected needles, from mother-to-child during pregnancy, at birth or when breast feeding."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 53,
            "data": {
                "is_heading": 0,
                "text": "3.7.2 CD4 cells, also known as T-helper cells, are white blood cells which play an essential part in the human immune system. One of their main roles is to detect pathogens and send signals to other types of immune cells, including CD8 killer cells, to destroy the infectious particles.CD4 cells are made in the spleen, lymph nodes and thymus gland. When HIV enters the body it targets and invades the CD4 cells in the blood. Once inside the CD4 cell the virus begins a complicated process of replication to produce new HIV virions. When completed, the new virions break through the cell wall and out into the bloodstream, destroying the CD4 cell. The new HIV virions then move to invade other CD4 cells and the process is repeated."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 54,
            "data": {
                "is_heading": 0,
                "text": "3.7.3 A normal CD4 count in someone who is uninfected and otherwise healthy is between 500 and 1,500 cells/\u00b5L of blood. Following HIV infection, the number of CD4 cells will gradually fall and"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 55,
            "data": {
                "is_heading": 0,
                "text": "if untreated, the CD4 will reach a level where the immune system is compromised and the person becomes susceptible to opportunistic infections and HIV related cancers."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 56,
            "data": {
                "is_heading": 0,
                "text": "3.7.4 There is no cure for HIV. Antiretroviral therapy can prevent further damage to the immune system by stopping the virus at different stages from cell invasion to replication preventing a further fall in the CD4 count. Early diagnosis of HIV infection reduces the risk of a person reaching a critically low CD4 count and experiencing serious health problems."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 57,
            "data": {
                "is_heading": 1,
                "prefix": 3.8,
                "text": "HIV in pregnancy"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 58,
            "data": {
                "is_heading": 0,
                "text": "3.8.1 Mother-to-child vertical transmission is now rare in the UK following the widespread implementation of routine antenatal screening, antiretroviral treatment in pregnancy and avoidance of breastfeeding."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 59,
            "data": {
                "is_heading": 0,
                "text": "3.8.2 The risk of mother-to-child HIV transmission in an untreated woman in pregnancy is around 25%. However, with early diagnosis, effective treatment and subsequent viral suppression, the risk of transmission is now very low (under 0.5%)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 60,
            "data": {
                "is_heading": 0,
                "text": "3.8.3 In the UK and Ireland, information is sought on all pregnancies in diagnosed HIV positive women through the National Study of HIV in Pregnancy and Childhood (NSHPC). Among more than 12,000 pregnancies reported between 2000 and2011 there was a four-fold drop in the rate of mother-to-child transmission from 2.1%to 0.46%. Mother-to-child transmission rates continue to decline."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 61,
            "data": {
                "is_heading": 1,
                "prefix": 4.0,
                "text": "Roles and Responsibilities"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 62,
            "data": {
                "is_heading": 0,
                "prefix": 4.1,
                "text": "The Specialist Nurse for Guidelines and Audit is responsible for ensuring clinical policies, guidelines and SOPs, are evidence-based and developed in line with national guidelines and following appropriate consultation."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 63,
            "data": {
                "is_heading": 0,
                "prefix": 4.2,
                "text": "The clinical director is responsible for the implementation of this guideline within the directorate."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 64,
            "data": {
                "is_heading": 0,
                "prefix": 4.3,
                "text": "The Head of Midwifery, maternity matrons and maternity managers are responsible for ensuring maternity staff are aware of the guideline and implement it."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 65,
            "data": {
                "is_heading": 0,
                "prefix": 4.4,
                "text": "The Obstetric Clinical Lead Consultant and Labour Ward Lead Consultant are responsible for ensuring the implementation of this guideline within the clinical setting."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 66,
            "data": {
                "is_heading": 0,
                "prefix": 4.5,
                "text": "All maternity staff are responsible for ensuring they are familiar with this guideline in relation to their practice and have the appropriate skills to implement this guideline."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 67,
            "data": {
                "is_heading": 1,
                "prefix": 5.0,
                "text": "Routine Screening in the Antenatal Clinic"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 68,
            "data": {
                "is_heading": 1,
                "prefix": 5.1,
                "text": "Screening is a process of identifying apparently healthy people who may be at increased risk of a disease or condition. They can then be offered information, further tests and appropriate treatment to reduce their risk and/or any complications arising from the disease or condition. The UK National Screening Committee (UK NSC) recommends that systematic, population"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 69,
            "data": {
                "is_heading": 0,
                "text": "screening in pregnancy is offered and recommended to all eligible women for:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 70,
            "data": {
                "is_heading": 0,
                "text": "Human immunodeficiency virus (HIV);"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 71,
            "data": {
                "is_heading": 0,
                "text": "Syphilis;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 72,
            "data": {
                "is_heading": 0,
                "text": "Hepatitis B;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 73,
            "data": {
                "is_heading": 0,
                "text": "Informed consent must be obtained prior to the specimen being taken."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 74,
            "data": {
                "is_heading": 1,
                "prefix": 12.0,
                "text": "All pregnant women should be provided with written information \u2018Screening tests for you and your baby' prior to their booking appointment. This is available in English and  other languages, via  www.gov.uk/government/publications/screening-tests-for-you-and-your-baby- description-in-brief ."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 75,
            "data": {
                "is_heading": 0,
                "prefix": 5.3,
                "text": "In order to make an informed decision regarding antenatal screening, an official translator or interpreting services should be offered for women who do not have English as their first language. It is not acceptable to use friends or family to translate. In Broomfield Maternity Big Word Interpreting services can be accessed 24/7."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 76,
            "data": {
                "is_heading": 0,
                "prefix": 5.4,
                "text": "For women with learning disabilities, physical disabilities or communication difficulties provisions should be made by Maternity services to ensure that these individuals have access to information and care."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 77,
            "data": {
                "is_heading": 1,
                "prefix": 5.5,
                "text": "When the midwife completes the woman's booking and discusses the various blood tests; bloods must be taken at booking or within 5 days for the booking (where not possible at booking). The booking midwife should review the blood results within 10 days of the sample being taken and for them to follow up with women for samples to be taken or repeated where required."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 78,
            "data": {
                "is_heading": 0,
                "prefix": 5.6,
                "text": "The midwife should clearly document whether the screening has been accepted or declined and whether a blood sample has been obtained in the handheld notes."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 79,
            "data": {
                "is_heading": 1,
                "prefix": 5.7,
                "text": "Offer of bloods to late bookers"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 80,
            "data": {
                "is_heading": 0,
                "prefix": 24.0,
                "text": "Women who book after  weeks of pregnancy should have blood samples marked as urgent. Test results should be available after  hours of receipt of sample at laboratory."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 81,
            "data": {
                "is_heading": 1,
                "prefix": 5.8,
                "text": "Declined Screening"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 82,
            "data": {
                "is_heading": 0,
                "text": "Where women decline screening tests the midwife who offered the initial screening should inform them they will be contacted by the Screening Team to discuss their choices."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 83,
            "data": {
                "is_heading": 0,
                "prefix": 5.9,
                "text": "Women should be contacted by the Screening team as soon as possible and ideally before 20 weeks to discuss their decision to decline screening and ensure that they are fully aware of the benefits of screening for infectious diseases for them and their baby."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 84,
            "data": {
                "is_heading": 0,
                "prefix": 5.1,
                "text": "Reoffer the screening test and arrange testing and follow up of results."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 85,
            "data": {
                "is_heading": 0,
                "prefix": 5.11,
                "text": "The onus of the reoffer is to facilitate an informed choice and not to coerce women to accept screening."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 86,
            "data": {
                "is_heading": 1,
                "prefix": 5.12,
                "text": "Women who miscarry or terminate their pregnancy following screening"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 87,
            "data": {
                "is_heading": 0,
                "text": "Screen positive- The Screening Team will contact the woman either by phone or in writing within 10 working days of the positive result to facilitate appropriate onward referral into specialist services and close the maternity care episode"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 88,
            "data": {
                "is_heading": 0,
                "prefix": 5.13,
                "text": "Screen negative- The Screening Team will write to the woman to inform her of her negative results for her screening tests"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 89,
            "data": {
                "is_heading": 1,
                "prefix": 5.14,
                "text": "Failsafe of Screening Results"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 90,
            "data": {
                "is_heading": 0,
                "text": "5.14.1 The Failsafe Officer monitors the eligible population from their referral for care ensuring that all women who accept screening have it performed."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 91,
            "data": {
                "is_heading": 0,
                "text": "5.14.2 Maternity Phlebotomist will review all women on the daily scan list for 1st trimester scans, they review all the screening results and check for completion of screening \u2013 these results are checked by a Antenatal Clinic or Screening Midwife, if any results are missing; these bloods will be taken with consent after the scan."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 92,
            "data": {
                "is_heading": 0,
                "text": "5.14.3 The Failsafe Officer will carry out a failsafe check following the woman's 1st trimester scan to ensure  all  screening results  are  available and  to  highlight  any  that  are  abnormal  to the screening midwives; this acts as a failsafe for abnormal results also. If any results are found to be missing, the following steps are followed."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 93,
            "data": {
                "is_heading": 0,
                "text": "5.14.4 Screening team will send one letter to the woman regarding the need to have bloods taken."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 94,
            "data": {
                "is_heading": 1,
                "prefix": 5.15,
                "text": "Women Presenting in Labour without an Antenatal Screening Blood Result"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 95,
            "data": {
                "is_heading": 0,
                "text": "Women presenting in labour, who have not been previously for antenatal care at the Trust are recommended to be offered testing for HIV, Hepatitis B, and Syphilis on first contact. The sample should be marked as urgent. (See appendix E. for Standard operating procedure for Out of Hours screening bloods.)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 96,
            "data": {
                "is_heading": 1,
                "prefix": 5.16,
                "text": "Results: Management of results"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 97,
            "data": {
                "is_heading": 1,
                "text": "5.16.1 Screen negative results: All women should be notified of their screening test result before or at the next antenatal visit. The result should be recorded in the health records."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 98,
            "data": {
                "is_heading": 0,
                "text": "5.16.2 The healthcare professional notifying the woman of her negative result should inform the woman that she was negative at the time of testing and offer the woman sexual health advice. She should be informed that she can request screening at any stage in her pregnancy if she deems herself at risk or changes her sexual partner"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 99,
            "data": {
                "is_heading": 1,
                "text": "5.16.3 Confirmed screen positive results: The laboratory will directly inform the Antenatal Screening Team of the screen positive result; this is done via the screening generic email address \u2013 Antenataland.newbornscreening@nhs.net and via phone ext 3433. (See Antenatal Management of HIV Positive Mothers section)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 100,
            "data": {
                "is_heading": 0,
                "text": "5.16.4 The Screening Team will contact the woman and arrange a consultation to discuss the results within 10 working days of the result being available to them from the Laboratory (as per National Standards for Screening)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 101,
            "data": {
                "is_heading": 1,
                "text": "5.16.5 Inconclusive results: The Screening Team will contact the woman and inform her of the inconclusive result and the need for a repeat sample within 2 weeks after the initial sample was taken to exclude recent infection."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 102,
            "data": {
                "is_heading": 1,
                "prefix": 5.17,
                "text": "New Diagnosis"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 103,
            "data": {
                "is_heading": 0,
                "text": "5.17.1 If this is a new diagnosis, repeat bloods are required to obtain confirmation of the initial results."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 104,
            "data": {
                "is_heading": 0,
                "text": "5.17.2 Women diagnosed with HIV for the first time during pregnancy, may experience significant psychosocial stress and trauma as a result of the diagnosis in the context of pregnancy, and will therefore require the support of an MDT of experienced carers."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 105,
            "data": {
                "is_heading": 0,
                "text": "5.17.3 A new HIV diagnosis may precipitate a complex mix of emotional, psychosocial, relationship, economic and, sometimes, legal issues."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 106,
            "data": {
                "is_heading": 0,
                "text": "5.17.4 The newly diagnosed pregnant woman also has a relatively brief time in which to develop trust in her medical carers and attain sufficient medical knowledge of her situation to be able to make informed decisions that will affect her long-term health, as well as that of her baby and her partner."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 107,
            "data": {
                "is_heading": 0,
                "text": "5.17.5 In the case of newly diagnosed HIV in pregnancy, prompt linkage to HIV care is beneficial, as is the offer of psychological support soon after an antenatal HIV diagnosis"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 108,
            "data": {
                "is_heading": 0,
                "text": "5.17.6 The HIV clinic will be contacted and an appointment arranged to be seen for a full review and screening, counselling and plan of care."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 109,
            "data": {
                "is_heading": 0,
                "text": "5.17.7 The patient will have a named Obstetric Consultant who will liaise with the HIV Consultant and HIV Specialist Nurse to document a plan of care for pregnancy and delivery in the patient's hand held records."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 110,
            "data": {
                "is_heading": 1,
                "prefix": 5.18,
                "text": "Previously Known Infection"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 111,
            "data": {
                "is_heading": 1,
                "text": "5.18.1 Patients already known to be HIV positive should still be screened in pregnancy. 5.18.2The Antenatal Newborn Screening Co-ordinator needs to be informed of the pregnancy to"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 112,
            "data": {
                "is_heading": 0,
                "text": "arrange a multidisciplinary team approach for care."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 113,
            "data": {
                "is_heading": 0,
                "text": "5.18.3 The patient will have a named Obstetric Consultant who will liaise with the HIV Consultant and HIV Specialist Nurse to document a plan of care for pregnancy and delivery in the patient's hand held records."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 114,
            "data": {
                "is_heading": 1,
                "prefix": 6.0,
                "text": "Antepartum Management of HIV Positive Patients"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 115,
            "data": {
                "is_heading": 0,
                "prefix": 6.1,
                "text": "After the initial screening results, women will be contacted by the Screening Team and invited in to discuss screening results. Results are not discussed over the phone as this may be a new diagnosis and should be handled sensitively."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 116,
            "data": {
                "is_heading": 0,
                "prefix": 6.2,
                "text": "A second confirmatory HIV positive result (for new diagnosis) should be taken as soon as possible."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 117,
            "data": {
                "is_heading": 0,
                "prefix": 6.3,
                "text": "Referral to the Screening Team for a previously diagnosed patient or for new diagnosis; a Proforma for Management of HIV Positive Women in Pregnancy will be placed with the patient's hospital records by the Antenatal Newborn Screening Team."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 118,
            "data": {
                "is_heading": 0,
                "text": "(Refer to Appendix A)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 119,
            "data": {
                "is_heading": 0,
                "prefix": 6.4,
                "text": "Positive screening results should be available to health care professionals without compromising the patient's right to confidentiality."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 120,
            "data": {
                "is_heading": 1,
                "prefix": 6.5,
                "text": "Reassurance about confidentiality is extremely important, especially regarding family members and friends, who may not know the woman is living with HIV. Women from communities in which HIV is more common may be concerned about HIV \u2018disclosure-by- association' when discussing certain interventions, including taking medication during pregnancy, having a CS, and avoiding breastfeeding. Possible reasons such as the need to \u2018take vitamins', or having \u2018obstetric complications' and \u2018mastitis' may help the women feel more confident in explaining the need for certain procedures to persistent enquirers. Breaking confidentiality in order to inform a sexual partner of the index patient's positive HIV status is sanctioned as \u2018a last resort' by the WHO and GMC."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 121,
            "data": {
                "is_heading": 0,
                "prefix": 6.6,
                "text": "In line with Trust guidance, patient confidentiality must be adhered to. Documentation"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 122,
            "data": {
                "is_heading": 0,
                "text": "in the handheld records, including printed blood results must be with patient consent. All"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 123,
            "data": {
                "is_heading": 0,
                "text": "other documentation must be placed in the hospital records. (Refer to \u2018Confidentiality"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 124,
            "data": {
                "is_heading": 0,
                "text": "Policy'; register number 07011)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 125,
            "data": {
                "is_heading": 1,
                "prefix": 6.7,
                "text": "A critical component in the prevention of vertical transmission of HIV is to facilitate a woman's engagement in care from an MDT that can employ medical interventions and provide appropriate holistic support. The team comprises of:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 126,
            "data": {
                "is_heading": 1,
                "text": "HIV specialist \u2013 based in Coelho Clinic (HIV clinic), Broomfield Hospital;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 127,
            "data": {
                "is_heading": 1,
                "text": "Consultant Obstetrician \u2013 Miss Rao \u2013 based at Broomfield Hospital;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 128,
            "data": {
                "is_heading": 1,
                "text": "Specialist Screening Midwife \u2013 based at Broomfield Hospital;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 129,
            "data": {
                "is_heading": 1,
                "text": "Consultant Paediatrician \u2013 Dr Hassan \u2013 based at Broomfield Hospital."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 130,
            "data": {
                "is_heading": 1,
                "text": "6.7.1  There are strong links and regular communication between the MDT regarding patient care and results."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 131,
            "data": {
                "is_heading": 0,
                "prefix": 6.8,
                "text": "All women seen by the HIV team will be assessed for:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 132,
            "data": {
                "is_heading": 0,
                "prefix": 3.0,
                "text": "Genito-urinary tract infections on presentation and in the rd trimester if appropriate;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 133,
            "data": {
                "is_heading": 0,
                "prefix": 3.0,
                "text": "Treponema screening in rd trimester if appropriate;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 134,
            "data": {
                "is_heading": 0,
                "text": "CD4 lymphocytes;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 135,
            "data": {
                "is_heading": 0,
                "text": "Need for antiretroviral therapy;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 136,
            "data": {
                "is_heading": 0,
                "text": "Hepatitis B and C;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 137,
            "data": {
                "is_heading": 0,
                "text": "Baseline genotypic resistance assay."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 138,
            "data": {
                "is_heading": 0,
                "prefix": 6.9,
                "text": "Screening for genito-urinary infections and treponemal screening will be repeated on subsequent visits according to risk."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 139,
            "data": {
                "is_heading": 0,
                "prefix": 6.1,
                "text": "All HIV positive patients should have the following issues discussed with them in Antenatal Clinic with the Obstetric Consultant \u2013 1st appointment 16-18 weeks and Screening Team:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 140,
            "data": {
                "is_heading": 1,
                "prefix": 6.11,
                "text": "Mental Health - HIV is associated with a higher risk of poor mental health (around 30%) and women may experience significant psychosocial barriers to accessing HIV care such as HIV- related stigma, unemployment and lack of financial resources. It is therefore important to be aware that pregnancy and the postpartum period may precipitate new psychosocial issues, or indeed exacerbate existing issues, among women living with HIV."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 141,
            "data": {
                "is_heading": 1,
                "prefix": 6.12,
                "text": "Domestic Violence - Women living with HIV may be at risk of intimate partner violence during pregnancy, with a lifetime prevalence rate of intimate partner violence in pregnancy estimated to be 14% in women living with HIV in the UK."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 142,
            "data": {
                "is_heading": 1,
                "prefix": 6.13,
                "text": "Support - Many women living with HIV will have issues relating to social support and/or immigration. All pregnant women living with HIV should be routinely asked about their social situation as early as possible during their pregnancy and referred for appropriate specialist advice and support including community support from the community HIV support team (Metro Health)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 143,
            "data": {
                "is_heading": 1,
                "prefix": 6.14,
                "text": "Contraception -  A plan for contraception to be used postnatally should be discussed antenatal with each woman. Antiretroviral therapy may need to be changed postnatally to align with a woman's choice of contraception. Further guidance on contraception in HIV can be found in the BASHH/BHIVA/FSRH Guidelines on the Sexual and Reproductive Healthcare of People Living with HIV."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 144,
            "data": {
                "is_heading": 1,
                "prefix": 2.0,
                "text": "Scans - Women are offered st and nd trimester screening in line with national recommendations. Where women screen as an increased chance for Trisomy 13, 18 or 21, Non Invasive Prenatal Testing (NIPT) should be recommended as this has the best sensitivity and specificity and will minimise the number of women who may need invasive testing."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 145,
            "data": {
                "is_heading": 1,
                "prefix": 6.16,
                "text": "Women on ART with severe hyperemesis will need support to continue their treatment."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 146,
            "data": {
                "is_heading": 1,
                "prefix": 6.17,
                "text": "Women with HIV are at risk of iatrogenic preterm delivery."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 147,
            "data": {
                "is_heading": 1,
                "prefix": 36.0,
                "text": "Women on ART also are at risk of hepatotoxicity, therefore LFT's should be monitored at least once in every trimester. Serial growth scans will be arranged for 28, 32 and  weeks to monitor fetal growth; these will be reviewed by the Obstetrician in Antenatal clinic."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 148,
            "data": {
                "is_heading": 1,
                "prefix": 6.19,
                "text": "The combination of HIV, chronic HBV infection  and pregnancy presents unique management considerations. Referral to the local designated specialist should be undertaken to ensure that all aspects of care are addressed, including the effects of HBV/HIV on pregnancy, effects of pregnancy on the course of co-infection, antiretroviral management for both HBV and HIV, and prevention of vertical transmission for both viruses."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 149,
            "data": {
                "is_heading": 1,
                "prefix": 6.2,
                "text": "Women with a history of genital herpes should be offered suppressive Acyclovir 400mg PO/TDS daily from 32 weeks gestation to reduce the HSV shedding, especially when planning for a normal vaginal delivery"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 150,
            "data": {
                "is_heading": 1,
                "prefix": 6.21,
                "text": "Lead Carer \u2013 Women will be offered to have all her routine antenatal care with her local Community Midwife or she can attend the Antenatal Clinic and have care with the Screening Team; this decision is down to the individual choice of the woman and how comfortable she feels discussing her care."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 151,
            "data": {
                "is_heading": 0,
                "prefix": 6.22,
                "text": "Prescription for mother and baby treatment post-delivery is requested by the Screening team from the Coelho Clinic and sent to pharmacy for the drugs to be issued, these are then stored in a locked cupboard on Labour Ward from 35 weeks gestation."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 152,
            "data": {
                "is_heading": 0,
                "prefix": 6.23,
                "text": "The prescription label contains the information that the medication cannot be removed from Labour Ward without the consent from the Antenatal and Newborn Screening team."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 153,
            "data": {
                "is_heading": 0,
                "prefix": 6.24,
                "text": "The woman's prescription chart will be securely fastened to the medication records until required in the intrapartum period."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 154,
            "data": {
                "is_heading": 1,
                "prefix": 7.0,
                "text": "Mother-to-Child Transmission of HIV"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 155,
            "data": {
                "is_heading": 0,
                "prefix": 7.1,
                "text": "Vertical transmission of HIV is reduced by mother's compliance with the medication and avoidance of breast-feeding."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 156,
            "data": {
                "is_heading": 0,
                "prefix": 7.2,
                "text": "If the mother would like to breastfeed then further support should be offered."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 157,
            "data": {
                "is_heading": 0,
                "prefix": 7.3,
                "text": "Monitoring of the breastfed infant will be offered monthly for a HIV RNA viral load testing during and 2 months after stopping breastfeeding."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 158,
            "data": {
                "is_heading": 1,
                "prefix": 8.0,
                "text": "Antiretroviral Therapy"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 159,
            "data": {
                "is_heading": 0,
                "prefix": 8.1,
                "text": "The data regarding the safety of antiretroviral therapy in pregnancy is still evolving. It is now generally considered that rates of congenital birth defects in children exposed to ART is similar to the rates seen in the general population. The management of HIV positive patients requires careful consideration of the balance between:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 160,
            "data": {
                "is_heading": 0,
                "text": "The patient's own health needs;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 161,
            "data": {
                "is_heading": 0,
                "text": "The need to reduce vertical transmission;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 162,
            "data": {
                "is_heading": 0,
                "text": "Possible adverse effects of antiretroviral therapy on the neonate and the mother;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 163,
            "data": {
                "is_heading": 0,
                "text": "Possible adverse effects of maternal HIV related disease on the fetus."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 164,
            "data": {
                "is_heading": 0,
                "prefix": 8.2,
                "text": "The patient will be offered antiretroviral therapy (ART), the choice of which will depend on their clinical status, CD4 count, viral load and other baseline investigations."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 165,
            "data": {
                "is_heading": 0,
                "prefix": 8.3,
                "text": "ART is not licenced for use in pregnancy except for the Zidovudine in the third trimester. There is a global consensus that women once started on ART should continue throughout pregnancy and lifelong."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 166,
            "data": {
                "is_heading": 0,
                "prefix": 8.4,
                "text": "All women not on ART should be started by 24 weeks and LFTs should be monitored 2 to 4 weeks after starting ART to detect hepatotoxicity and IRIS (immune reconstitution inflammatory syndrome)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 167,
            "data": {
                "is_heading": 0,
                "prefix": 8.5,
                "text": "In one study, women on Dolutegravir were found to have a higher risk of neural tube defects (3:1000 compared with 1:1000) although other studies have not shown this. Women trying to conceive and choosing to continue on Dolutegravir should be taking folic acid 5 md OD."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 168,
            "data": {
                "is_heading": 0,
                "prefix": 8.6,
                "text": "Best safety data in pregnancy are on Efavirenz and Atazanavir \u2013 these should be considered first line in pregnancy"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 169,
            "data": {
                "is_heading": 1,
                "prefix": 9.0,
                "text": "Zidovudine Monotherapy"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 170,
            "data": {
                "is_heading": 0,
                "prefix": 9.1,
                "text": "Zidovudine monotherapy is not recommended and should only be used in women"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 171,
            "data": {
                "is_heading": 1,
                "text": "declining ART with a viral load of <10,000 HIV RNA copies/mL and willing to have a caesarean section (CS)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 172,
            "data": {
                "is_heading": 1,
                "prefix": 9.2,
                "text": "Triple therapy is recommended (BHIVA guideline section 6.2) \u201cAll pregnant women, including elite controllers, should start ART during pregnancy and be advised to continue lifelong treatment\u201d and recommended ART is triple therapy (section 6.3)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 173,
            "data": {
                "is_heading": 1,
                "prefix": 10.0,
                "text": "Antiretroviral Therapy (ART)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 174,
            "data": {
                "is_heading": 0,
                "prefix": 10.1,
                "text": "Patients who require therapy for their HIV disease should be given ART according to BHIVA guidelines. This will be guided by genotypic resistance tests. Where the lady is at risk of or has presented with an opportunistic infection, the initiation of ART should not be delayed due to a pregnancy."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 175,
            "data": {
                "is_heading": 1,
                "prefix": 11.0,
                "text": "Patients who conceive on Therapy"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 176,
            "data": {
                "is_heading": 0,
                "prefix": 11.1,
                "text": "Patients who conceive on ART should be advised to continue their current therapy. Many patients will not realise their pregnant state until well into the period of organogenesis and this practice has not been shown to confer additional risk."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 177,
            "data": {
                "is_heading": 0,
                "prefix": 11.2,
                "text": "Furthermore, there is a theoretical concern that viral rebound may occur with \u2018structured treatment interruptions' which might be associated with a significant CD4  decline jeopardizing maternal health and potentially resulting in reactivation of infections associated with congenital abnormalities."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 178,
            "data": {
                "is_heading": 0,
                "prefix": 11.3,
                "text": "If the mother's treatment is failing, then this should be changed appropriately to ensure the lowest possible viral load at the time of delivery. Only in exceptional circumstances should therapy be changed during the first trimester."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 179,
            "data": {
                "is_heading": 1,
                "prefix": 12.0,
                "text": "Patients who present at 28 weeks Gestation or Later"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 180,
            "data": {
                "is_heading": 0,
                "prefix": 12.1,
                "text": "Patients presenting at 28 weeks gestation or later will be managed on an individual case basis."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 181,
            "data": {
                "is_heading": 0,
                "prefix": 12.2,
                "text": "ART will be commenced as soon as possible by the HIV team and not Obstetric team;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 182,
            "data": {
                "is_heading": 0,
                "prefix": 12.3,
                "text": "Urgent referral to HIV clinic and screening team required."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 183,
            "data": {
                "is_heading": 1,
                "prefix": 13.0,
                "text": "Viral Load"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 184,
            "data": {
                "is_heading": 0,
                "prefix": 13.1,
                "text": "Viral load is an important determinant of transmission and should be measured as and the result shared with the screening team, Lead Obstetric Consultant and the HIV clinic:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 185,
            "data": {
                "is_heading": 0,
                "text": "When blood is taken for the second (confirmatory) HIV test;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 186,
            "data": {
                "is_heading": 0,
                "prefix": 36.0,
                "text": "Every 3 months (at least) and at week  in women on established therapy;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 187,
            "data": {
                "is_heading": 0,
                "text": "Two weeks after starting or changing therapy;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 188,
            "data": {
                "is_heading": 0,
                "text": "At delivery."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 189,
            "data": {
                "is_heading": 1,
                "prefix": 14.0,
                "text": "Genotypic Resistance Testing"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 190,
            "data": {
                "is_heading": 0,
                "prefix": 14.1,
                "text": "Genotypic resistance testing will be checked:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 191,
            "data": {
                "is_heading": 0,
                "text": "Pre-treatment with antiretrovirals (baseline);"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 192,
            "data": {
                "is_heading": 0,
                "text": "If viral load does not decrease on treatment;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 193,
            "data": {
                "is_heading": 0,
                "text": "If viral load rebounds following an undetectable level;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 194,
            "data": {
                "is_heading": 0,
                "text": "At delivery if on monotherapy."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 195,
            "data": {
                "is_heading": 1,
                "prefix": 15.0,
                "text": "Pneumocystis Carinii Pneumonia (PCP) prophylaxis"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 196,
            "data": {
                "is_heading": 0,
                "prefix": 15.1,
                "text": "If the patient's CD4 count is persistently below 200 cells/uL, pneumocystis carinii pneumonia (PCP) prophylaxis will be recommended."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 197,
            "data": {
                "is_heading": 0,
                "prefix": 15.2,
                "text": "The treatment of choice is co-trimoxazole 960mg once a day unless the patient is allergic, in which case refer to the HIV team."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 198,
            "data": {
                "is_heading": 0,
                "prefix": 15.3,
                "text": "Co-trimoxazole could result in structural defects when given in the first trimester. However, the risks of PCP induced hypoxia to both mother and fetus far outweigh the risks of teratogenicity in the neonate."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 199,
            "data": {
                "is_heading": 0,
                "prefix": 15.4,
                "text": "Regular administration of folic acid 5 mg appears to negate the risk of fetal malformations. The 5mg folic acid tablet is usually prescribed."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 200,
            "data": {
                "is_heading": 1,
                "prefix": 16.0,
                "text": "Complications during Pregnancy"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 201,
            "data": {
                "is_heading": 0,
                "prefix": 16.1,
                "text": "The side effects of antiretrovirals may present in a similar manner to the complications of pregnancy such as pre-eclampsia, cholestasis or other liver dysfunction."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 202,
            "data": {
                "is_heading": 0,
                "prefix": 16.2,
                "text": "Lactic acidosis with hepatic steatosis is a rare side effect of antiretrovirals. Typical initial symptoms have included 1-6 weeks nausea and vomiting, abdominal pain, dyspnoea and weakness."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 203,
            "data": {
                "is_heading": 0,
                "prefix": 16.3,
                "text": "Any patient presenting with vomiting, malaise or oedema should be investigated for:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 204,
            "data": {
                "is_heading": 0,
                "text": "Acidosis;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 205,
            "data": {
                "is_heading": 0,
                "text": "Hepatitis;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 206,
            "data": {
                "is_heading": 0,
                "text": "Pancreatitis;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 207,
            "data": {
                "is_heading": 0,
                "text": "Disseminated intravascular coagulation."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 208,
            "data": {
                "is_heading": 0,
                "text": "(whether or not the patient has hypertension or proteinuria)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 209,
            "data": {
                "is_heading": 0,
                "prefix": 16.4,
                "text": "If there is a lactate acidaemia/acidosis discontinuation of antiretroviral therapy must be seriously considered."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 210,
            "data": {
                "is_heading": 0,
                "prefix": 16.5,
                "text": "Advice can be obtained from consultant in general and respiratory medicine, consultant physician in HIV, the on-call general medical registrar and/or the on-call HIV registrar at Barts (0207 3777 000)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 211,
            "data": {
                "is_heading": 1,
                "prefix": 17.0,
                "text": "External cephalic version in patients with HIV"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 212,
            "data": {
                "is_heading": 0,
                "prefix": 50.0,
                "text": "ECV can be offered to women with plasma viral load under  copies/mL."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 213,
            "data": {
                "is_heading": 1,
                "prefix": 18.0,
                "text": "HIV-2 Infected Patients"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 214,
            "data": {
                "is_heading": 0,
                "prefix": 18.1,
                "text": "HIV-2 is endemic in West Africa and other areas of high prevalence include parts of India and Portugal. It appears to be less pathogenic than HIV-1 with prolonged periods of asymptomatic infection and slower rates of disease progression reflecting in a lower rate of viral replication."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 215,
            "data": {
                "is_heading": 0,
                "prefix": 18.2,
                "text": "Management of HIV-2 infected pregnant patients has not been clearly defined. Latest BHIVA guidelines should be consulted for further advice. If HIV-2 viral load is known to be <50 copies/mL, then antepartum/postpartum intervention maybe unnecessary.  Non-nucleoside reverse transcriptase inhibitors must not be prescribed since they have little inhibitory activity against HIV-2."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 216,
            "data": {
                "is_heading": 0,
                "prefix": 18.3,
                "text": "Vaginal birth may be an option if the HIV-2 viral load is undetectable."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 217,
            "data": {
                "is_heading": 0,
                "prefix": 18.4,
                "text": "Vertical transmission of HIV-2 is less common than of HIV-1, between 0% and 4%."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 218,
            "data": {
                "is_heading": 1,
                "prefix": 19.0,
                "text": "Neonatologist Referral"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 219,
            "data": {
                "is_heading": 0,
                "text": "(Refer to the guideline for \u2018Management of Neonates Born to HIV+ve Mother Guideline'; register number 07056)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 220,
            "data": {
                "is_heading": 0,
                "prefix": 19.1,
                "text": "A neonatal alert form should be completed and sent to the Screening Office located in the Antenatal Clinic. A copy of the alert form is retained for the screening office records and a copy is forwarded to the named paediatric consultant for a plan of care post-delivery. (Refer to the \u2018Guideline for calling paediatric staff and for obtaining paediatric referral'; register number 09113)(Refer to Appendix B)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 221,
            "data": {
                "is_heading": 0,
                "prefix": 19.2,
                "text": "When the named paediatric consultant has completed the neonatal alert form with a care plan, a copy will be retained in the neonatal folder. A further copy will be sent to the Antenatal and Newborn Screening team; who will then provide a subsequent copy for the Labour Ward folder. The Antenatal and Newborn Screening Co-ordinator will provide a copy which should be filed in the patient's lilac folder."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 222,
            "data": {
                "is_heading": 1,
                "prefix": 20.0,
                "text": "HIV and Hepatitis B and C Co-infected Patients"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 223,
            "data": {
                "is_heading": 0,
                "prefix": 20.1,
                "text": "All co-infected patients should be treated with combination antiretroviral therapy. Patients co- infected with hepatitis B should be treated with a combination which includes drugs with activity against hepatitis B. Patients co-infected with hepatitis C should be offered elective lower segment caesarean section (LSCS)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 224,
            "data": {
                "is_heading": 1,
                "text": "Pre Term SROM"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 225,
            "data": {
                "is_heading": 1,
                "prefix": 20.2,
                "text": "In women who have a detectable viral load it may be possible to optimise their ART regimen to reduce the risk of vertical transmission"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 226,
            "data": {
                "is_heading": 0,
                "prefix": 20.3,
                "text": "The management of preterm SROM at \u226534 weeks is the same as that of term SROM,"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 227,
            "data": {
                "is_heading": 0,
                "text": "except that women at 34\u201337 weeks' gestation will require group B streptococcus prophylaxis in line with national guidelines."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 228,
            "data": {
                "is_heading": 0,
                "prefix": 20.4,
                "text": "When preterm SROM occurs at <34 weeks:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 229,
            "data": {
                "is_heading": 0,
                "text": "Intramuscular steroids should be administered in accordance with national guidelines;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 230,
            "data": {
                "is_heading": 0,
                "text": "Where HIV viral load is not controlled, this should be optimised;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 231,
            "data": {
                "is_heading": 0,
                "text": "There should be multidisciplinary discussion about the timing and mode of delivery."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 232,
            "data": {
                "is_heading": 1,
                "prefix": 21.0,
                "text": "Intrapartum Management"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 233,
            "data": {
                "is_heading": 0,
                "prefix": 21.1,
                "text": "ECV for breech presentation can be performed at term from 37+0 weeks of gestation in women with viral load <50 copies/mL. In nulliparous women, ECV may be offered from 36+0 weeks of gestation,"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 234,
            "data": {
                "is_heading": 0,
                "prefix": 21.2,
                "text": "This will depend on the 36 weeks (or most recent) viral load, the hepatitis C status and the patient's antiretroviral therapy.(Refer to Appendix E)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 235,
            "data": {
                "is_heading": 0,
                "prefix": 21.3,
                "text": "For women taking ART, a decision regarding recommended mode of delivery should be made after review of plasma viral load results at 36 weeks."
            }
        },
        {
            "type": "table",
            "sequence_num": 236,
            "data": {
                "num_rows": 3,
                "num_cols": 2,
                "table_items": [
                    {
                        "text": "Viral Load <50 copies/mL at 36 weeks"
                    },
                    {
                        "text": "In the absence of obstetric contraindications, planned vaginal delivery should be supported."
                    },
                    {
                        "text": "Viral load of 50\u2013399 copies/mL at 36 weeks"
                    },
                    {
                        "text": "Pre-labour CS should be considered, taking into account the actual viral load, the trajectory of the viral load, length of time on treatment, adherence issues, obstetric factors and the woman's views."
                    },
                    {
                        "text": "Viral load is \u2265400 HIV RNA copies/mL at 36 weeks"
                    },
                    {
                        "text": "PLCS is recommended."
                    }
                ]
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 237,
            "data": {
                "is_heading": 1,
                "prefix": 38.0,
                "text": "Where the indication for CS is the prevention of vertical transmission, CS should be undertaken at between  and 39 weeks' gestation."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 238,
            "data": {
                "is_heading": 1,
                "prefix": 21.5,
                "text": "Where PLCS is undertaken only for obstetric indications and plasma viral load is <50 copies/mL,  the  usual  obstetric  considerations  apply  and  the  CS  will  usually  be performed after 39 weeks' gestation. The time of CS is balanced between the risk of spontaneous labour and the risk of Transient Tachypnoea of the Newborn (TTN) which is 1:300 at 39 weeks and doubles for every week earlier that delivery occurs."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 239,
            "data": {
                "is_heading": 1,
                "prefix": 24.0,
                "text": "In women for whom a vaginal delivery has been planned and labour has commenced, obstetric management should follow the same guidelines as for the HIV-negative population, apart from duration of ruptured membranes \u2013 aim for delivery within  hours"
            }
        },
        {
            "type": "table",
            "sequence_num": 240,
            "data": {
                "num_rows": 4,
                "num_cols": 1,
                "table_items": [
                    {
                        "text": "In all cases of term pre-labour SROM, delivery within 24 hours should be the aim."
                    },
                    {
                        "text": "If maternal HIV viral load is <50 copies/mL, immediate induction or augmentation of labour is recommended in women who have pre-labour SROM, with a low threshold for treatment of intrapartum pyrexia. For all women with viral load <50 copies/mL, obstetric management should aim for delivery within 24 hours of SROM."
                    },
                    {
                        "text": "For women with SROM and a last measured plasma viral load of 50\u2013399 copies/mL, immediate CS is recommended, but should take into account the actual viral load, the trajectory of the viral load, length of time on treatment, adherence issues, obstetric factors and the woman's views."
                    },
                    {
                        "text": "For women with SROM and maternal HIV viral load \u2265400 copies/mL, immediate CS is recommended."
                    }
                ]
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 241,
            "data": {
                "is_heading": 0,
                "prefix": 21.7,
                "text": "Traditionally amniotomy, fetal scalp electrodes and blood sampling, instrumental delivery and episiotomy have been avoided in HIV infection because of theoretical transmission risks. Data from the pre-ART era have been reviewed, and show little or no risk for many of these procedures."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 242,
            "data": {
                "is_heading": 0,
                "prefix": 21.8,
                "text": "Vaginal birth after CS (VBAC) can be offered to if viral load <50 copies/mL."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 243,
            "data": {
                "is_heading": 0,
                "prefix": 21.9,
                "text": "On the day of delivery the patient should take her antiretroviral medication as prescribed even if nil by mouth. This should not be stopped post delivery unless on the advice of in accordance with the medical respiratory/HIV physician management plan."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 244,
            "data": {
                "is_heading": 0,
                "prefix": 21.1,
                "text": "All women with HIV are recommended to give birth in settings with good access to paediatric care."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 245,
            "data": {
                "is_heading": 0,
                "prefix": 21.11,
                "text": "Women who chose water birth should be supported if the viral load is less then 50 copies/mL. There is scanty safety evidence to support water birth."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 246,
            "data": {
                "is_heading": 1,
                "prefix": 22.0,
                "text": "Intravenous Zidovudine Regimen"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 247,
            "data": {
                "is_heading": 0,
                "prefix": 22.1,
                "text": "Intrapartum intravenous zidovudine infusion is recommended in the following circumstances:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 248,
            "data": {
                "is_heading": 0,
                "prefix": 22.2,
                "text": "For women with a viral load of >1000 copies/mL plasma who present in labour, or with ruptured membranes or who are admitted for planned CS."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 249,
            "data": {
                "is_heading": 0,
                "prefix": 22.3,
                "text": "For untreated women presenting in labour or with ruptured membranes in whom the current viral load is not known."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 250,
            "data": {
                "is_heading": 0,
                "prefix": 22.4,
                "text": "In women on zidovudine monotherapy undergoing a PLCS intravenous zidovudine can be considered."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 251,
            "data": {
                "is_heading": 0,
                "prefix": 22.5,
                "text": "The patient should be commenced on IV zidovudine infusion either:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 252,
            "data": {
                "is_heading": 1,
                "text": "Four hours before LSCS;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 253,
            "data": {
                "is_heading": 1,
                "text": "In established labour if delivering vaginally."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 254,
            "data": {
                "is_heading": 1,
                "prefix": 22.6,
                "text": "If LSCS is indicated on obstetric grounds this should not be delayed"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 255,
            "data": {
                "is_heading": 1,
                "prefix": 23.0,
                "text": "Management of Unplanned Delivery"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 256,
            "data": {
                "is_heading": 1,
                "prefix": 23.1,
                "text": "Women presenting in labour/with spontaneous rupture of the membranes (SROM)/requiring delivery without a documented HIV result must be advised to have an urgent HIV test. A reactive/positive result must be acted upon immediately, with initiation of interventions to prevent vertical transmission of HIV without waiting for further/formal serological confirmation."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 257,
            "data": {
                "is_heading": 0,
                "prefix": 23.2,
                "text": "This may involve the clinical management of preterm labour, unknown viral load and possibly no antenatal care."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 258,
            "data": {
                "is_heading": 1,
                "prefix": 23.3,
                "text": "Antiretroviral therapy must be discussed with the medical respiratory/HIV physician. In most cases, IV Zidovudine regimen is going to be recommended if delivery is anticipated."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 259,
            "data": {
                "is_heading": 0,
                "prefix": 23.4,
                "text": "Getting ready to administer this regimen will be prudent whilst awaiting further advice."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 260,
            "data": {
                "is_heading": 0,
                "prefix": 23.5,
                "text": "In most cases LSCS should be recommended. The incidence of vertical transmission increases rapidly after 4 hours of ruptured membranes."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 261,
            "data": {
                "is_heading": 0,
                "prefix": 23.6,
                "text": "Delivery should never be delayed to complete the IV Zidovudine regimen."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 262,
            "data": {
                "is_heading": 0,
                "prefix": 23.7,
                "text": "If there is a premature rupture of membranes the risk of HIV transmission must be balanced against the risks of premature delivery. Corticosteroids should be given as indicated."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 263,
            "data": {
                "is_heading": 1,
                "prefix": 24.0,
                "text": "Perinatal mental health in women with HIV"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 264,
            "data": {
                "is_heading": 1,
                "prefix": 24.1,
                "text": "Women with HIV have higher risk of poor mental health. UK-based ASTRA study showed that depressive symptoms in women with HIV are 30%."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 265,
            "data": {
                "is_heading": 1,
                "prefix": 24.2,
                "text": "The prevalence of postnatal depression (PND) in women with HIV living in high income settings is between 30-53%"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 266,
            "data": {
                "is_heading": 1,
                "prefix": 24.3,
                "text": "Women with HIV have an lifetime prevalence rate of intimate partner violence of 14%"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 267,
            "data": {
                "is_heading": 1,
                "prefix": 24.4,
                "text": "All pregnant women should be asked about domestic violence"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 268,
            "data": {
                "is_heading": 0,
                "prefix": 24.5,
                "text": "Factors associated with PND in women living with HIV include past history of mental health issues, financial, immigration and housing concerns, lack of social support, HIV-related stigma, intimate partner violence, substance misuse and lack of support from a partner."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 269,
            "data": {
                "is_heading": 1,
                "prefix": 25.0,
                "text": "Postpartum Management and breastfeeding"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 270,
            "data": {
                "is_heading": 0,
                "prefix": 25.1,
                "text": "Stopping ART after delivery is not recommended; women who wish to stop ART should be counselled on the risks and managed by Coelho Clinic."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 271,
            "data": {
                "is_heading": 0,
                "prefix": 25.2,
                "text": "All HIV positive mothers should have their viral load checked at delivery. If the mother was taking zidovudine monotherapy, genotypic resistance should also be checked."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 272,
            "data": {
                "is_heading": 0,
                "prefix": 25.3,
                "text": "The safest way to feed babies of mothers with HIV is formula milk. Women not breastfeeding should be offered Carbergoline to supress lactation."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 273,
            "data": {
                "is_heading": 0,
                "prefix": 25.4,
                "text": "For further advice see the contact sheet in Appendix D."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 274,
            "data": {
                "is_heading": 0,
                "prefix": 25.5,
                "text": "Information leaflets on breastfeeding for women who are HIV positive are available on the BHIVA website under the heading Additional information:  BHIVA guidelines for the management of HIV in pregnancy and postpartum 2018 (2020 third interim update)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 275,
            "data": {
                "is_heading": 1,
                "prefix": 26.0,
                "text": "Neonatal Management"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 276,
            "data": {
                "is_heading": 1,
                "prefix": 26.1,
                "text": "(Refer to the guideline entitled \u2018Management of infants born to HIV positive mother'; register number 07056)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 277,
            "data": {
                "is_heading": 1,
                "prefix": 27.0,
                "text": "Staff and Training"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 278,
            "data": {
                "is_heading": 0,
                "prefix": 27.1,
                "text": "All midwifery and obstetric staff must attend yearly mandatory training, which includes maternal antenatal screening tests."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 279,
            "data": {
                "is_heading": 0,
                "prefix": 27.2,
                "text": "All paediatric, neonatal , obstetric and midwifery staff are to ensure that their knowledge and skills are up to date in order to complete their portfolio for appraisal."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 280,
            "data": {
                "is_heading": 1,
                "prefix": 27.3,
                "text": "Guideline Management"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 281,
            "data": {
                "is_heading": 0,
                "text": "27.3.1 As an integral part of the knowledge, skills framework, staff are appraised annually to ensure competency in computer skills and the ability to access the current approved guidelines via the Trust's intranet site."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 282,
            "data": {
                "is_heading": 1,
                "prefix": 28.0,
                "text": "Infection Prevention"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 283,
            "data": {
                "is_heading": 0,
                "prefix": 28.1,
                "text": "HIV is a blood borne virus and all staff should follow the Trusts guideline on infection control, using aseptic non-touch technique (ANNT) when taking bloods and wearing the appropriate uniform i.e. non-sterile gloves."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 284,
            "data": {
                "is_heading": 0,
                "prefix": 28.2,
                "text": "All staff should ensure that they follow Trust guidelines on infection prevention. All invasive devices must be inserted and cared for using High Impact Intervention guidelines to reduce the risk of infection and deliver safe care. This care should be recorded in the Saving Lives High Impact Intervention Monitoring Tool Paperwork (Medical Devices)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 285,
            "data": {
                "is_heading": 1,
                "prefix": 29.0,
                "text": "Audit and Monitoring"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 286,
            "data": {
                "is_heading": 0,
                "text": "."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 287,
            "data": {
                "is_heading": 0,
                "prefix": 29.1,
                "text": "Audit of compliance with this guideline will be considered on an annual audit basis in accordance with the Clinical Audit Strategy and Policy, the Maternity annual audit work plan and the NHSLA requirements. The Audit Lead in liaison with the Risk Management Group will identify a lead for the audit."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 288,
            "data": {
                "is_heading": 0,
                "prefix": 29.2,
                "text": "As a minimum the following specific requirements will be monitored:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 289,
            "data": {
                "is_heading": 0,
                "text": "Designated lead for antenatal screening in the maternity service;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 290,
            "data": {
                "is_heading": 0,
                "text": "Antenatal screening tests, which follow the UK National Screening Committee guidance;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 291,
            "data": {
                "is_heading": 0,
                "text": "System for ensuring that appropriate tests are undertaken within appropriate timescales;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 292,
            "data": {
                "is_heading": 0,
                "text": "System for ensuring that appropriate tests are undertaken when patients book late;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 293,
            "data": {
                "is_heading": 0,
                "text": "Process for the review of the results;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 294,
            "data": {
                "is_heading": 0,
                "text": "Process for reporting all results to patients;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 295,
            "data": {
                "is_heading": 0,
                "text": "Process for reporting results to other relevant healthcare professionals;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 296,
            "data": {
                "is_heading": 0,
                "text": "Process for ensuring that women with screen positive test results are referred and managed within appropriate timescales;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 297,
            "data": {
                "is_heading": 0,
                "text": "Maternity service's expectations for staff training, as identified in the training needs analysis;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 298,
            "data": {
                "is_heading": 0,
                "text": "Process for audit, multidisciplinary review of results and subsequent monitoring of action plans."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 299,
            "data": {
                "is_heading": 0,
                "prefix": 29.3,
                "text": "A review of a suitable sample will be audited from the health care records of patients who have delivered to evidence the process for ensuring that patients with screen positive test results are referred and managed  within appropriate timescales. A  minimum compliance 75% is required for each requirement. Where concerns are identified more frequent audit will be undertaken."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 300,
            "data": {
                "is_heading": 0,
                "prefix": 29.4,
                "text": "The findings of the audit will be reported to and approved by the Multi-disciplinary Risk Management Group (MRMG) and an action plan with named leads and timescales will be developed to address any identified deficiencies. Performance against the action plan will be monitored by this group at subsequent meetings."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 301,
            "data": {
                "is_heading": 0,
                "prefix": 29.5,
                "text": "The audit report will be reported to the monthly Women's and Children's and Sexual Health Directorate Governance Meeting (DGM) and significant concerns relating to compliance will be entered on the local Risk Assurance Framework."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 302,
            "data": {
                "is_heading": 0,
                "prefix": 29.6,
                "text": "Key findings and learning points from the audit will be submitted to the Patient Safety Group within the integrated learning report."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 303,
            "data": {
                "is_heading": 0,
                "prefix": 29.7,
                "text": "Key findings and learning points will be disseminated to relevant staff."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 304,
            "data": {
                "is_heading": 1,
                "prefix": 30.0,
                "text": "Approval and Implementation"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 305,
            "data": {
                "is_heading": 0,
                "prefix": 30.1,
                "text": "All policies, procedures and guidelines will be circulated clinically and professional approval confirmed by the Asset Owner prior to submission to the Controlled Document team for ratification by the Joint Document Management Group."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 306,
            "data": {
                "is_heading": 0,
                "prefix": 30.2,
                "text": "It is the Guidelines and Audit Nurse's and author's responsibility to inform appropriate Maternity Services' staff of the approved policy documents when they are uploaded to the Trust's Intranets."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 307,
            "data": {
                "is_heading": 1,
                "prefix": 31.0,
                "text": "References"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 308,
            "data": {
                "is_heading": 0,
                "text": "NHS Public Health Functions Agreement (2016-17) Service Specification No:15 NHS Infectious Diseases in Pregnancy Screening Programme."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 309,
            "data": {
                "is_heading": 0,
                "text": "BHIVA (2014) Guidelines for the management of HIV infection in pregnant women. HIV Medicine (2014), 15 (Suppl. 4), 1\u201377."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 310,
            "data": {
                "is_heading": 0,
                "text": "BHIVA (2013) Guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy. HIV Medicine (2014), 15 (Suppl. 1), 1\u201385."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 311,
            "data": {
                "is_heading": 0,
                "text": "PHE (2016) Infectious Diseases in Pregnancy Screening Programme. Programme Standards."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 312,
            "data": {
                "is_heading": 1,
                "text": "Appendix A"
            }
        },
        {
            "type": "image",
            "sequence_num": 313,
            "data": {
                "url": "08056 Management of human immunodeficiency virus (HIV) in pregnancy 5.1.003.png"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 314,
            "data": {
                "is_heading": 1,
                "text": "Management of Human Immunodeficiency Virus (HIV) Positive Women in Pregnancy First Name  Surname"
            }
        },
        {
            "type": "image",
            "sequence_num": 315,
            "data": {
                "url": "08056 Management of human immunodeficiency virus (HIV) in pregnancy 5.1.004.png"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 316,
            "data": {
                "is_heading": 1,
                "text": "NHS No  Hospital No  DOB"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 317,
            "data": {
                "is_heading": 1,
                "text": "EDD  Date of Diagnosis"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 318,
            "data": {
                "is_heading": 1,
                "text": "Antenatal Newborn Screening Co-ordinator"
            }
        },
        {
            "type": "image",
            "sequence_num": 319,
            "data": {
                "url": "08056 Management of human immunodeficiency virus (HIV) in pregnancy 5.1.005.png"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 320,
            "data": {
                "is_heading": 0,
                "text": "Contacted / seen by Antenatal Newborn Screening Team  No  Yes Second confirmatory blood sample required  No  Yes"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 321,
            "data": {
                "is_heading": 0,
                "text": "Date Taken  __________________________________ Previous Diagnosis  No  Yes Referral to HIV Team  No  Yes"
            }
        },
        {
            "type": "image",
            "sequence_num": 322,
            "data": {
                "url": "08056 Management of human immunodeficiency virus (HIV) in pregnancy 5.1.007.png"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 323,
            "data": {
                "is_heading": 0,
                "text": "Consultant(s) name and contact details:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 324,
            "data": {
                "is_heading": 0,
                "text": "_______________________________________________________________________________________________________"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 325,
            "data": {
                "is_heading": 0,
                "text": "Date  __________________________________ Print Name  __________________________________  Signature  __________________________________"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 326,
            "data": {
                "is_heading": 1,
                "text": "Antenatal Care Plan"
            }
        },
        {
            "type": "image",
            "sequence_num": 327,
            "data": {
                "url": "08056 Management of human immunodeficiency virus (HIV) in pregnancy 5.1.008.png"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 328,
            "data": {
                "is_heading": 0,
                "text": "Antenatal Clinic Appointment 16-18 weeks gestation  No  Yes Neonatal Unit Alert form completed and sent  No  Yes Anaesthetic Appointment booked  No  Yes Medication ordered from pharmacy (35/40)  No  Yes"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 329,
            "data": {
                "is_heading": 0,
                "text": "Date Taken  __________________________________"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 330,
            "data": {
                "is_heading": 0,
                "text": "Medication received on Labour Ward  No   Yes   Date Taken  __________________________________"
            }
        },
        {
            "type": "image",
            "sequence_num": 331,
            "data": {
                "url": "08056 Management of human immunodeficiency virus (HIV) in pregnancy 5.1.009.png"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 332,
            "data": {
                "is_heading": 0,
                "text": "Date  __________________________________ Print Name  __________________________________  Signature  __________________________________"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 333,
            "data": {
                "is_heading": 1,
                "text": "Antenatal Discussion of the Benefits and Risks"
            }
        },
        {
            "type": "image",
            "sequence_num": 334,
            "data": {
                "url": "08056 Management of human immunodeficiency virus (HIV) in pregnancy 5.1.011.png"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 335,
            "data": {
                "is_heading": 0,
                "text": "Antiretroviral Therapy  No  Yes Vertical Transmission  No  Yes Avoidance of Breast Feeding  No  Yes Mode of Delivery  No  Yes"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 336,
            "data": {
                "is_heading": 0,
                "text": "Date  __________________________________ Print Name  __________________________________  Signature  __________________________________"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 337,
            "data": {
                "is_heading": 1,
                "text": "Management Plan for Delivery"
            }
        },
        {
            "type": "image",
            "sequence_num": 338,
            "data": {
                "url": "08056 Management of human immunodeficiency virus (HIV) in pregnancy 5.1.012.png"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 339,
            "data": {
                "is_heading": 1,
                "text": "Elective Caesarean Section  No  Yes Vaginal Delivery  No  Yes Comments"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 340,
            "data": {
                "is_heading": 0,
                "text": "Date __________________________________ Print Name __________________________________ Signature __________________________________"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 341,
            "data": {
                "is_heading": 1,
                "text": "Appendix B"
            }
        },
        {
            "type": "image",
            "sequence_num": 342,
            "data": {
                "url": "08056 Management of human immunodeficiency virus (HIV) in pregnancy 5.1.013.png"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 343,
            "data": {
                "is_heading": 1,
                "text": "NEONATAL ALERT WITHIN MATERNITY AND NEONATAL SERVICES"
            }
        },
        {
            "type": "table",
            "sequence_num": 344,
            "data": {
                "num_rows": 6,
                "num_cols": 2,
                "table_items": [
                    {
                        "text": "First Name"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "Surname"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "Hospital / NHS Number"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "EDD"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "Reason for Neonatal Alert"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "Referred by / Date (Please print)"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "Postnatal Plan made by Paediatric Team"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "Plan Written by / Date (Please print)"
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 345,
            "data": {
                "is_heading": 1,
                "text": "Referral criteria overleaf"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 346,
            "data": {
                "is_heading": 1,
                "text": "CRITERIA FOR REFERRAL"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 347,
            "data": {
                "is_heading": 1,
                "text": "Please note this list is a guide but does not cover all referrals, if a referral is inappropriate the alert form will be returned to the referring clinician, if in doubt complete a form."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 348,
            "data": {
                "is_heading": 0,
                "text": "MC/DA Twins (If any concerns) or multiple births >2 fetus"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 349,
            "data": {
                "is_heading": 0,
                "text": "Maternal Infectious Disease - HIV, Hepatitis B, Syphilis"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 350,
            "data": {
                "is_heading": 0,
                "text": "Significant structural abnormalities diagnosed in the antenatal period"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 351,
            "data": {
                "is_heading": 0,
                "text": "Mothers with high antibody titres e.g Anti-D, C and Kell"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 352,
            "data": {
                "is_heading": 0,
                "text": "Any previous pregnancies with GBBS, Sepsis or Meningitis \u2013 in previous baby"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 353,
            "data": {
                "is_heading": 0,
                "text": "Severe oligohydramnios / SGA"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 354,
            "data": {
                "is_heading": 0,
                "text": "Abnormal Doppler's on ultrasound"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 355,
            "data": {
                "is_heading": 0,
                "text": "Genetic / hereditary conditions in the immediate family \u2013 siblings / parents of the baby"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 356,
            "data": {
                "is_heading": 0,
                "text": "Social issues \u2013 Drug or alcohol use in pregnancy"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 357,
            "data": {
                "is_heading": 0,
                "text": "Any other condition that may require paediatric input at birth \u2013 not required for women taken one SSID's (Sertraline, Citalopram, Fluoxetine etc.)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 358,
            "data": {
                "is_heading": 0,
                "text": "Management of Human Immunodeficiency Virus (HIV) in Maternity / 08056 / 5.1"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 359,
            "data": {
                "is_heading": 0,
                "prefix": 1.0,
                "text": ""
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 360,
            "data": {
                "is_heading": 1,
                "text": "RECEIVING HIV BLOOD RESULTS"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 361,
            "data": {
                "is_heading": 1,
                "text": "Appendix C"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 362,
            "data": {
                "is_heading": 1,
                "text": "Negative Results"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 363,
            "data": {
                "is_heading": 0,
                "text": "Management of Human Immunodeficiency Virus (HIV) in Maternity / 08056 / 5.1"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 364,
            "data": {
                "is_heading": 0,
                "prefix": 1.0,
                "text": ""
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 365,
            "data": {
                "is_heading": 0,
                "text": "Checked by a midwife in Antenatal Clinic or Community"
            }
        },
        {
            "type": "image",
            "sequence_num": 366,
            "data": {
                "url": "08056 Management of human immunodeficiency virus (HIV) in pregnancy 5.1.014.png"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 367,
            "data": {
                "is_heading": 0,
                "text": "Filed in notes"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 368,
            "data": {
                "is_heading": 0,
                "text": "Results sent to or inform the Antenatal Screening team of the result 01245 513433"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 369,
            "data": {
                "is_heading": 0,
                "text": "Monday -Friday 9.00 a.m. - 5.00 p.m."
            }
        },
        {
            "type": "image",
            "sequence_num": 370,
            "data": {
                "url": "08056 Management of human immunodeficiency virus (HIV) in pregnancy 5.1.015.png"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 371,
            "data": {
                "is_heading": 0,
                "text": "The blood test should be repeated by the Antenatal Screening team before a confirmed Positive/Negative HIV status is given to the woman"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 372,
            "data": {
                "is_heading": 0,
                "text": "Confirmed  Confirmed positive HIV status negative HIV"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 373,
            "data": {
                "is_heading": 0,
                "text": "status"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 374,
            "data": {
                "is_heading": 0,
                "text": "Sign result and  Inform Antenatal Screening team of file in maternity  positive result"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 375,
            "data": {
                "is_heading": 0,
                "text": "records  01245 513433 and via antenataland.newbornscreening@nhs.net"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 376,
            "data": {
                "is_heading": 0,
                "text": "Mon \u2013 Fri 9-5"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 377,
            "data": {
                "is_heading": 0,
                "text": "Reassure"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 378,
            "data": {
                "is_heading": 0,
                "text": "patient"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 379,
            "data": {
                "is_heading": 0,
                "text": "Antenatal screening team will arrange"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 380,
            "data": {
                "is_heading": 0,
                "text": "Miss Rao antenatal  Referral to HIV appointment  Specialist Team"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 381,
            "data": {
                "is_heading": 0,
                "text": "Follow Retroviral Infection Care Plan placed in maternity notes by Antenatal Screening Co-ordinator (also available on Antenatal Public Folders)"
            }
        },
        {
            "type": "image",
            "sequence_num": 382,
            "data": {
                "url": "08056 Management of human immunodeficiency virus (HIV) in pregnancy 5.1.016.png"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 383,
            "data": {
                "is_heading": 1,
                "text": "Appendix D"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 384,
            "data": {
                "is_heading": 1,
                "text": "Contact Names and Telephone Numbers"
            }
        },
        {
            "type": "table",
            "sequence_num": 385,
            "data": {
                "num_rows": 5,
                "num_cols": 2,
                "table_items": [
                    {
                        "text": "Contact name:"
                    },
                    {
                        "text": "Telephone no:"
                    },
                    {
                        "text": "Consultant Microbiologist"
                    },
                    {
                        "text": "01245 516311"
                    },
                    {
                        "text": "Consultant Microbiologist"
                    },
                    {
                        "text": "01245 516312"
                    },
                    {
                        "text": "GUM Clinical Nurse Specialist"
                    },
                    {
                        "text": "01245 315907"
                    },
                    {
                        "text": "Antenatal and Newborn Screening Team"
                    },
                    {
                        "text": "01245 513433"
                    }
                ]
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 386,
            "data": {
                "is_heading": 0,
                "text": "Management of Human Immunodeficiency Virus (HIV) in Maternity / 08056 / 5.1"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 387,
            "data": {
                "is_heading": 0,
                "prefix": 1.0,
                "text": ""
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 388,
            "data": {
                "is_heading": 0,
                "text": "Management of Human Immunodeficiency Virus (HIV) in Maternity / 08056 / 5.1"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 389,
            "data": {
                "is_heading": 1,
                "text": "Appendix E"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 390,
            "data": {
                "is_heading": 1,
                "text": "Antenatal and Newborn Screening \u2013 HIV Screening Standard Operating Procedure"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 391,
            "data": {
                "is_heading": 0,
                "text": "Women refer for Antenatal Care"
            }
        },
        {
            "type": "image",
            "sequence_num": 392,
            "data": {
                "url": "08056 Management of human immunodeficiency virus (HIV) in pregnancy 5.1.017.png"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 393,
            "data": {
                "is_heading": 0,
                "text": "Referral processed and initial booking appointment arranged to see Midwife \u2013 letter sent to women with information regarding their booking appointment, scan date"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 394,
            "data": {
                "is_heading": 0,
                "text": "Antenatal Booking Performed ideally before 10 weeks, screening discussed and screening offered for HIV Screening. Screening tests for you and your baby booklet given"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 395,
            "data": {
                "is_heading": 1,
                "text": "Screening Negative Results  Miscarried / Termination  Screening Positive Results"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 396,
            "data": {
                "is_heading": 1,
                "text": "of pregnancy"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 397,
            "data": {
                "is_heading": 1,
                "text": "Copy of blood result emailed to Results reviewed by Community  Screening Team via nhs.net email \u2013"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 398,
            "data": {
                "is_heading": 1,
                "text": "Midwife, results given to woman at  Letter sent to  Letter sent to  Antenataland.newbornscreening"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 399,
            "data": {
                "is_heading": 1,
                "text": "16 week check  woman to inform of  woman to"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 400,
            "data": {
                "is_heading": 1,
                "text": "negative result by  contact  @nhs.net and followed up with screening team  screening team  phone call informing of result."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 401,
            "data": {
                "is_heading": 1,
                "text": "Woman contacted and appointment arranged to see and discuss results"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 402,
            "data": {
                "is_heading": 1,
                "prefix": 2.0,
                "text": "Seen/Counselled by Screening Midwives \u2013Information Leaflet given appropriate to result, nd Blood sample taken for confirmatory testing and sent to the laboratory, support given to woman and plan of care made for pregnancy."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 403,
            "data": {
                "is_heading": 1,
                "text": "No further action  Results \u2013 Negative  Results \u2013 Positive"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 404,
            "data": {
                "is_heading": 1,
                "text": "Inform woman of results,"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 405,
            "data": {
                "is_heading": 1,
                "text": "If negative result \u2013 Arrange Obstetric Consultant appointment  If Positive result \u2013 Arrange Coelho Clinic (HIV team) review for review, clear documentation in hand held notes  and Obstetric Consultant appointment for review,"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 406,
            "data": {
                "is_heading": 1,
                "text": "Plan of care fed back to screening team from Coelho Clinic team and notes / hospital records updated, neonatal alert completed and sent to Neonatal Consultant for postnatal plan of care for baby."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 407,
            "data": {
                "is_heading": 1,
                "text": "Screening Team to arrange Serial growth scans in pregnancy to monitor baby, Coelho Clinic will monitor Viral load during pregnancy and determine medication required in pregnancy and following delivery"
            }
        },
        {
            "type": "image",
            "sequence_num": 408,
            "data": {
                "url": "08056 Management of human immunodeficiency virus (HIV) in pregnancy 5.1.018.png"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 409,
            "data": {
                "is_heading": 1,
                "text": "Neonatal Consultant aware of results \u2013Neonatal Alert Completed, filed in mother's notes and on Delivery Suite, Screening team will arrange prescription for mother and baby (via Coelho Clinic) ready for delivery at 35 weeks, prescription to be taken to Delivery suite ready for delivery. Obstetric Consultant review at 36-38 weeks to decide plan and mode of delivery."
            }
        },
        {
            "type": "image",
            "sequence_num": 410,
            "data": {
                "url": "08056 Management of human immunodeficiency virus (HIV) in pregnancy 5.1.019.png"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 411,
            "data": {
                "is_heading": 1,
                "prefix": 1.0,
                "text": "Following Delivery, Neonatal Doctors to be called to  Mother to be reminded of the need or baby to have follow Delivery Suite to prescribe and administer st dose of anti- up clinic appointments with the paediatric team and baby to"
            }
        },
        {
            "type": "image",
            "sequence_num": 412,
            "data": {
                "url": "08056 Management of human immunodeficiency virus (HIV) in pregnancy 5.1.021.png"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 413,
            "data": {
                "is_heading": 1,
                "text": "retro viral for baby, dose calculated on baby's weight have daily medication until review"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 414,
            "data": {
                "is_heading": 0,
                "prefix": 29.0,
                "text": ""
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 415,
            "data": {
                "is_heading": 1,
                "text": "Appendix F Out of Hours Screening pathway for Un-booked Women or Women with No Infectious Diseases Screening Results in Maternity"
            }
        },
        {
            "type": "image",
            "sequence_num": 416,
            "data": {
                "url": "08056 Management of human immunodeficiency virus (HIV) in pregnancy 5.1.022.png"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 417,
            "data": {
                "is_heading": 0,
                "text": "Maternity Services"
            }
        },
        {
            "type": "image",
            "sequence_num": 418,
            "data": {
                "url": "08056 Management of human immunodeficiency virus (HIV) in pregnancy 5.1.023.png"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 419,
            "data": {
                "is_heading": 0,
                "text": "Responsibilities Woman presents un-booked or women with no recorded screening results for infectious diseases will need immediate transfer to Delivery suite, Health professional seeing woman should contact Labour +W  ard Coordinator Ext 3057 or Delivery Suite Register \u2013 Bleep 3500"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 420,
            "data": {
                "is_heading": 0,
                "text": "Laboratory Services"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 421,
            "data": {
                "is_heading": 0,
                "text": "Responsibilities"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 422,
            "data": {
                "is_heading": 0,
                "text": "Labour Ward Coordinator to ensure Woman to be taken to Delivery Suite for 1:1 care, screening bloods should be"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 423,
            "data": {
                "is_heading": 0,
                "text": "discussed and taken immediately and sent as urgent, if not booked \u2013 to be completed on Delivery suite, Labour Ward"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 424,
            "data": {
                "is_heading": 0,
                "text": "Out of Hours  Coordinator to inform Registrar and On call Consultant and Manger on call of patient admission and SBAR,  In Hours"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 425,
            "data": {
                "is_heading": 1,
                "text": "Manager on Call to be contacted and to contact Microbiology BMS On- call to come in to process bloods.  Labour Ward Coordinator to contact Microbiology BMS on Ext. 5052 to Blood sample to be marked as URGENT and sent to the laboratory URGENTLY by the Porters to go to  initiate screening for Hepatitis B, HIV, and Syphilis"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 426,
            "data": {
                "is_heading": 1,
                "text": "\u2013 West Wing Microbiology Fridge C352, DO NOT PUT SAMPLES IN THE POD"
            }
        },
        {
            "type": "table",
            "sequence_num": 427,
            "data": {
                "num_rows": 3,
                "num_cols": 2,
                "table_items": [
                    {
                        "text": "Any Positive results will be relayed by the testing technical member of staff back to the Labour Ward Coordinator."
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "The Laboratory BMS On-Call will attend the laboratory and will perform testing \u2013 they will attend ASAP, turnaround time for results is expected to be approx. 2 hoursIn the event of technical difficulty, additional testing may be provided by a tertiary testing laboratory and will be organised by the on-site laboratory at MEHT"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 428,
            "data": {
                "is_heading": 1,
                "text": "The Negative results will be passed back directly by the technical member of staff to Labour Ward Coordinator on ext 3057."
            }
        },
        {
            "type": "table",
            "sequence_num": 429,
            "data": {
                "num_rows": 1,
                "num_cols": 1,
                "table_items": [
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 430,
            "data": {
                "is_heading": 0,
                "text": "Microbiology BMS will email the Screening urgent screening, a"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 431,
            "data": {
                "is_heading": 0,
                "text": "Screening team will liaise with the midwi midwives around"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 432,
            "data": {
                "is_heading": 1,
                "text": "Failsafe Officer to be informed of the woman and to be added to the appropriate Cohort Failsafe Tracker  HIV \u2013 Baby  Hepatitis B  Syphilis \u2013 to have  Positive \u2013  Baby to had"
            }
        },
        {
            "type": "image",
            "sequence_num": 433,
            "data": {
                "url": "08056 Management of human immunodeficiency virus (HIV) in pregnancy 5.1.026.png"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 434,
            "data": {
                "is_heading": 0,
                "prefix": 2019.0,
                "text": "Labour Ward Coordinator to contact pharmacy for anti-retro viral  Zidovudine  Vaccination of  assessment by Developed by Emma Neate, Screening Coordinator for Maternity  medication  within 4  baby ? need for  the Neonatal  and John Livermore, Interim Pathology Services Manager,  hours of  Immunoglobulin  Team and plan  January  / Updated 2.8.21 Emma Neate delivery (see  within 24 hours  of care made"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 435,
            "data": {
                "is_heading": 0,
                "prefix": 31.0,
                "text": "If baby already delivered when results received, neonatal team to be  guideline) of delivery (see  (see guideline) contacted and informed urgently for treatment plan  guideline)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 436,
            "data": {
                "is_heading": 1,
                "text": "Appendix G: Preliminary Equality Analysis"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 437,
            "data": {
                "is_heading": 1,
                "text": "This assessment relates to: Management of Human Immunodeficiency Virus (HIV) in Maternity / 08056"
            }
        },
        {
            "type": "table",
            "sequence_num": 438,
            "data": {
                "num_rows": 3,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "\u2610 A change in a service to patients"
                    },
                    {
                        "text": "\u2612 A change to an existing policy"
                    },
                    {
                        "text": "\u2610 A change to the way staff work"
                    },
                    {
                        "text": "\u2610 A new policy"
                    },
                    {
                        "text": "\u2610 Something else (please give details)"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 439,
            "data": {
                "num_rows": 7,
                "num_cols": 2,
                "table_items": [
                    {
                        "text": "Questions"
                    },
                    {
                        "text": "Answers"
                    },
                    {
                        "text": "1."
                    },
                    {
                        "text": "What are you proposing to change?"
                    },
                    {
                        "text": "Review of Current Guidelines in line with British HIV Association Guideline"
                    },
                    {
                        "text": "2."
                    },
                    {
                        "text": "Why are you making this change? (What will the change achieve?)"
                    },
                    {
                        "text": "Review of Current Guidelines in line with British HIV Association Guideline"
                    },
                    {
                        "text": "3."
                    },
                    {
                        "text": "Who benefits from this change and how?"
                    },
                    {
                        "text": "Patients and Clinicians"
                    },
                    {
                        "text": "4."
                    },
                    {
                        "text": "Is anyone likely to suffer any negative impact as a result of this change? If no, please record reasons here and sign and date this assessment. If yes, please complete a full EIA."
                    },
                    {
                        "text": "No"
                    },
                    {
                        "text": "5."
                    },
                    {
                        "text": "a) Will you be undertaking any consultation as part of this change?"
                    },
                    {
                        "text": "Yes"
                    },
                    {
                        "text": "b) If so, with whom?"
                    },
                    {
                        "text": "Refer to pages 1 & 2"
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 440,
            "data": {
                "num_rows": 2,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "Preliminary analysis completed by:"
                    },
                    {
                        "text": "Name"
                    },
                    {
                        "text": "Emma Neate"
                    },
                    {
                        "text": "Job Title"
                    },
                    {
                        "text": "Screening Co-ordinator"
                    },
                    {
                        "text": "13 February 2020"
                    }
                ]
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 441,
            "data": {
                "is_heading": 0,
                "prefix": 32.0,
                "text": ""
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 442,
            "data": {
                "is_heading": 0,
                "text": "Management of Human Immunodeficiency Virus (HIV) in Maternity / 08056 / 5.1"
            }
        }
    ]
}